HAEMONETICS CORPHAEEarnings & Financial Report
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
HAE Q3 FY2026 Key Financial Metrics
Revenue
$339.0M
Gross Profit
$202.4M
Operating Profit
$67.4M
Net Profit
$44.7M
Gross Margin
59.7%
Operating Margin
19.9%
Net Margin
13.2%
YoY Growth
-2.7%
EPS
$0.95
HAEMONETICS CORP Q3 FY2026 Financial Summary
HAEMONETICS CORP reported revenue of $339.0M (down 2.7% YoY) for Q3 FY2026, with a net profit of $44.7M (up 19.3% YoY) (13.2% margin). Cost of goods sold was $136.6M, operating expenses totaled $135.0M.
Key Financial Metrics
| Total Revenue | $339.0M |
|---|---|
| Net Profit | $44.7M |
| Gross Margin | 59.7% |
| Operating Margin | 19.9% |
| Report Period | Q3 FY2026 |
Revenue Breakdown
HAEMONETICS CORP Q3 FY2026 revenue of $339.0M breaks down across 3 segments, led by Hospital at $143.5M (42.3% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Hospital | $143.5M | 42.3% |
| Plasma Productsand Services | $138.9M | 41.0% |
| Blood Center Productsand Services | $56.6M | 16.7% |
HAEMONETICS CORP Revenue by Segment — Quarterly Trend
HAEMONETICS CORP revenue by segment across the last 4 reported quarters, showing how each business line (such as Hospital and Plasma Productsand Services) has evolved quarter over quarter.
| Segment | Q3 FY2026 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 |
|---|---|---|---|---|
| Hospital | $143.5M | $145.5M | $139.7M | $147.2M |
| Plasma Productsand Services | $138.9M | $125.4M | $129.9M | — |
| Blood Center Productsand Services | $56.6M | — | $51.8M | $54.3M |
HAEMONETICS CORP Annual Revenue by Year
HAEMONETICS CORP annual revenue history includes year-by-year totals (for example, 2025 revenue was $1.4B).
HAEMONETICS CORP Quarterly Revenue & Net Profit History
HAEMONETICS CORP results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2026 | $339.0M | -2.7% | $44.7M | 13.2% |
| Q2 FY2026 | $327.3M | -5.3% | $38.7M | 11.8% |
| Q1 FY2026 | $321.4M | -4.4% | $34.0M | 10.6% |
| Q4 FY2025 | $330.6M | — | $58.0M | 17.5% |
| Q3 FY2025 | $348.5M | +3.7% | $37.5M | 10.8% |
| Q2 FY2025 | $345.5M | +8.6% | $33.8M | 9.8% |
| Q1 FY2025 | $336.2M | — | $38.4M | 11.4% |
| Q3 FY2024 | $336.3M | +10.1% | $31.2M | 9.3% |
Income Statement
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $336.3M | $336.2M | $345.5M | $348.5M | $330.6M | $321.4M | $327.3M | $339.0M |
| YoY Growth | 10.1% | N/A | 8.6% | 3.7% | N/A | -4.4% | -5.3% | -2.7% |
Balance Sheet
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $2.20B | $2.54B | $2.53B | $2.53B | $2.45B | $2.46B | $2.44B | $2.49B |
| Liabilities | $1.26B | $1.64B | $1.65B | $1.62B | $1.63B | N/A | N/A | N/A |
| Equity | $943.3M | $905.4M | $878.9M | $906.9M | $820.8M | $882.3M | $849.2M | $911.5M |
Cash Flow
| Q3 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-540000 | $-27.4M | $48.8M | $43.8M | $116.6M | $17.4M | $111.3M | $93.6M |